Protalix BioTherapeutics (PLX) Revenue (2010 - 2026)

Protalix BioTherapeutics' Revenue history runs 17 years deep, the most recent figure standing at $33.8 million for Q1 2026.

• On a quarterly basis, Revenue rose 233.73% year-over-year to $33.8 million in Q1 2026; TTM through Mar 2026 was $76.4 million, a 27.8% increase from a year earlier, with the FY2025 full-year figure at $52.7 million, down 1.23% from the prior year.
• Revenue advanced to $33.8 million in Q1 2026 per PLX's latest filing, from $9.1 million in the prior quarter.
• Across five years, Revenue topped out at $35.1 million in Q2 2023 and bottomed at $3.7 million in Q1 2024.
• The 5-year median for Revenue is $13.5 million (2024), against an average of $14.9 million.
• Across the five-year window, Revenue jumped 300.72% in 2023 and plunged 61.59% in 2024, its largest moves.
• Year by year, Revenue stood at $8.6 million in 2022, then gained by 21.69% to $10.5 million in 2023, then jumped by 73.74% to $18.2 million in 2024, then tumbled by 49.93% to $9.1 million in 2025, then soared by 269.98% to $33.8 million in 2026.
• Per Business Quant, the three latest PLX Revenue figures stand at $33.8 million (Q1 2026), $9.1 million (Q4 2025), and $17.9 million (Q3 2025).